Compare Gilead Sciences, Inc. (GILD) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs IAC/Interactivecorp — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while IAC/Interactivecorp trades at $40.88 (market cap $3.05B). The key difference: Gilead Sciences, Inc. is far larger — about 59.8× IAC/Interactivecorp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and IAC/Interactivecorp for 79 Days on average.
| GILD | PPLI | |
|---|---|---|
Market Cap | $182.40B | $3.05B |
Volume | 4,469,821 | 931,019 |
Sector | Health | Media |
52-Week High | $155.80 | $47.62 |
52-Week Low | $116.74 | $31.52 |
Typical Hold Time | 111 Days | 79 Days |
Enterprise Value | $205.46B | $3.53B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
PPLI trades at $40.89, up 0.74% with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility - missing Q4 2025 and Q1 2026 but beating Q2 2026 expectations. Revenue declined to $2.39B in 2025 while maintaining healthy gross margins of 66.35%. The company's valuation appears attractive with P/E of 6.92 and P/B of 0.6, though negative cash flow of -$820M in 2025 raises concerns.
The outlook remains positive given potential MGM bid and improving 2026 profit projections (14.12% margin). Key risks include volatile earnings, declining revenue trends, and negative cash flow. With strong institutional support and takeover speculation, the stock offers upside potential but requires monitoring of operational turnaround and acquisition developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
